CLLS
Cellectis

2,608
Loading...
Loading...
News
all
press releases
This Penny Stock Has 270% Upside Potential in 2025. Is It a Buy Now?
Shares of this biotech company have had a rough ride in 2024, but analysts are feeling good about its future.
barchart.com·9mo ago
News Placeholder
More News
News Placeholder
Cellectis Upgraded to Buy: Here's Why
Cellectis S.A. (NASDAQ: CLLS) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is...
Benzinga·1y ago
News Placeholder
Cellectis (NASDAQ:CLLS) Shares Pass Above Fifty Day Moving Average of $2.74
Cellectis S.A. (NASDAQ:CLLS - Get Free Report) crossed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $2.74 and traded as high as $2.75. Cellectis...
Zolmax·2y ago
News Placeholder
Cellectis announces the drawdown of the second tranche of 15 million under the credit facility agreement entered with the European Investment Bank (EIB)
NEW YORK, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS NASDAQ: CLLS) (the Company ), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Globe Newswire·2y ago
News Placeholder
Cellectis SA (CLLS, $3.09) entered Downtrend as Momentum indicator drops below 0 level on Jan 02, 2024
This indicator may be signaling that CLLS's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...
Tickeron - Stocks·2y ago

Latest CLLS News

View

Advertisement|Remove ads.

Advertisement|Remove ads.